Johnson & Johnson Growth Led By Biosense Webster And Cerenovus
Executive Summary
Johnson & Johnson’s leadership remains optimistic about the future of its medical device divisions despite reporting a 2.6% revenue decline in the first six months of 2019 compared to the same period of 2018.
You may also be interested in...
J&J Finishes Tough Year With Optimism For 2021
J&J expects its medical device sales to begin growing rapidly by the middle of 2021 as the pandemic subsides.
J&J’s Investment In Medical Device Businesses Is Starting To Pay Off
Johnson & Johnson's medical device businesses grew 5.3% on an organic basis in the third quarter, led by the Biosense Webster electrophysiology business. The company is increasing R&D investment, especially in robotic surgery, to boost its surgery and orthopedics businesses.
Ethicon Expects Powered Circular Stapler To Address A Common Source Of Cancer Surgery Complications
The Echelon circular powered stapler for colorectal, gastric and thoracic surgery features Ethicon’s 3D stapling technology to evenly distribute compression and a gripping-surface technology that reduces compressive forces on tissue. The company expects the new system will reduce leaks at the staple line without compromising blood or lymphatic perfusion.